Michael Ehlers is to quit as head of Biogen’s troubled R&D outfit, taking a role as chief executive of New York-based venture capitalist Apple Tree Partners.
Novartis’ biosimilars and generics arm Sandoz has struck a deal with Polpharma Biologics to market a proposed biosimilar of Biogen’s multiple sclerosis drug Tysabri (natalizumab).<
Under threat from a gene therapy from Novartis, Biogen is making the case for its drug Spinraza for the muscle wasting disease spinal muscular atrophy, with new data that it hopes persuades
